The CEO of a small company that focuses on business development on behalf of its biopharma customers was under constant pressure to help them enter the best possible deals for assets in various phases of development.
The CEO and his team needed to understand comparable deals for valuations by stage and locate the best partners for each deal. They needed to determine the best timing to sell the asset. And they needed to be aware of trends in deal structures and see how changes might affect up-front payments, total payments and the associated risks of each.
The CEO could look at a deal and then quickly grasp the pipeline of drugs and the ongoing clinical trials in that space. Who was competing with his client in a particular therapeutic area and how far along were they?
Resource Sponsored By
Please fill out the form to access the content
